Testing two medications to reduce leukemia before stem cell transplant

This study is testing whether two medications called azacitidine and venetoclax can help eliminate or reduce remaining leukemia cells in people with acute myeloid leukemia (AML) who have already received standard chemotherapy. The goal is to make the cancer as undetectable as possible before patients receive a stem cell transplant from a donor — a procedure that gives them healthy new blood-forming cells to replace their diseased immune system and lower the chance the leukemia comes back.

Even after successful initial chemotherapy, tiny amounts of leukemia cells can remain hidden in the body, which increases the risk of cancer returning. This trial is testing whether giving this medication before a stem cell transplant can eliminate these remaining cells and improve long-term survival.